Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hepatitis

Free Subscription Articles published in J Hepatol Retrieve available abstracts of 212 articles: HTML format

Single Articles

March 2023
1. CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al
   Corrigendum to 'National trends in retreatment of HCV due to reinfection or treatment failure in Australia' (J Hepatol [2023] 260-270).
   J Hepatol. 2023 Mar 8:S0168-8278(23)00109-5. doi: 10.1016/j.jhep.2023.
   PubMed    
   
   
   
2. MONTALI I, Berti CC, Morselli M, Acerbi G, et al
   Deregulated intracellular pathways define novel molecular targets for HBV-specific CD8 T cell reconstitution in chronic hepatitis B.
   J Hepatol. 2023 Mar 7:S0168-8278(23)00167-8. doi: 10.1016/j.jhep.2023.
   PubMed     Abstract available
   
   
   
3. RICCIUTO A, Kamath BM, Hirschfield GM, Trivedi PJ, et al
   Primary sclerosing cholangitis and overlap features of autoimmune hepatitis: a coming of age or an age-ist problem?
   J Hepatol. 2023 Mar 2:S0168-8278(23)00162-9. doi: 10.1016/j.jhep.2023.
   PubMed     Abstract available
   
   
   February 2023
4. ENGELMANN C, Jalan R
   Authors' reply to: G-CSF exacerbates liver injury in a mouse model of autoimmune hepatitis.
   J Hepatol. 2023 Feb 25:S0168-8278(23)00110-1. doi: 10.1016/j.jhep.2023.
   PubMed    
   
   
   
5. LOHSE AW, Lorgensen MH
   Paediatric Autoimmune Hepatitis: time to change the textbooks?
   J Hepatol. 2023 Feb 23:S0168-8278(23)00105-8. doi: 10.1016/j.jhep.2023.
   PubMed    
   
   
   
6. RODRIGUEZ C, Marchand S, Sessa A, Cappy P, et al
   Orthohepevirus C hepatitis, an underdiagnosed disease?
   J Hepatol. 2023 Feb 18:S0168-8278(23)00096-X. doi: 10.1016/j.jhep.2023.
   PubMed    
   
   
   
7. CHALASANI N, Li YJ, Dellinger A, Navarro V, et al
   Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury.
   J Hepatol. 2023;78:293-300.
   PubMed     Abstract available
   
   
   
8. CARLSON S, Vaz K, Peterson A
   A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: has the correct patient cohort been targeted?
   J Hepatol. 2023 Feb 1:S0168-8278(23)00074-0. doi: 10.1016/j.jhep.2023.
   PubMed    
   
   
   January 2023
9. ZOULIM F, Testoni B
   Eliminating cccDNA to cure Hepatitis B virus (HBV) infection.
   J Hepatol. 2023 Jan 27:S0168-8278(23)00029-6. doi: 10.1016/j.jhep.2023.
   PubMed    
   
   
   
10. MAGGIORE G, Bernard O, Mosca A, Ballot E, et al
    Long-term outcomes of patients with type 1 or 2 autoimmune hepatitis presenting in childhood.
    J Hepatol. 2023 Jan 25:S0168-8278(23)00025-9. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
11. BURGER D, Aktas H, de Knegt R
    Sustained virological response in an HCV-infected patient on an enzyme-inducing anti-epileptic agent despite undetectable trough plasma levels of velpatasvir.
    J Hepatol. 2023 Jan 25:S0168-8278(23)00027-2. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    
12. LUCIFORA J, Alfaiate D, Pons C, Michelet M, et al
    Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms.
    J Hepatol. 2023 Jan 23:S0168-8278(23)00016-8. doi: 10.1016/j.jhep.2023.
    PubMed     Abstract available
    
    
    
13. MAALEJ NH, Collins IJ, Ades AE, Scott K, et al
    Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine.
    J Hepatol. 2023 Jan 17:S0168-8278(23)00014-4. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    
14. SANDMANN L, Tergast TL, Wedemeyer H, Deterding K, et al
    3P and 5P model of limited value for the detection of clinically significant portal hypertension in patients with hepatitis delta.
    J Hepatol. 2023 Jan 17:S0168-8278(23)00010-7. doi: 10.1016/j.jhep.2023.
    PubMed    
    
    
    December 2022
15. SU J, Brunner L, Oz EA, Sacherl J, et al
    Activation of CD4 T cells during prime immunization determines the success of a therapeutic hepatitis B vaccine in HBV-carrier mouse models.
    J Hepatol. 2022 Dec 30:S0168-8278(22)03465-1. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    
16. ADRANEDA C, Tan YC, Yeo EJ, Kew GS, et al
    A critique and systematic review of the clinical utility of hepatitis B core-related antigen.
    J Hepatol. 2022 Dec 28:S0168-8278(22)03469-9. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    
17. LEISKAU C, Tsaka S, Meyer-Ruhnke L, Mutschler FE, et al
    Acute severe non-A-E-hepatitis of unknown origin in children - a 30-year retrospective observational study from north-west Germany.
    J Hepatol. 2022 Dec 23:S0168-8278(22)03464-X. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    
18. CHOI WM, Cheuk-Fung Yip T, Lai-Hung Wong G, Kim WR, et al
    Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir-vs. entecavir-based regimens: individual patient data meta-analysis.
    J Hepatol. 2022 Dec 23:S0168-8278(22)03459-6. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    
19. SHEN Y, Liu Y, Yu K, Shen M, et al
    G-CSF exacerbates liver injury in a mouse model of autoimmune hepatitis.
    J Hepatol. 2022 Dec 16:S0168-8278(22)03414-6. doi: 10.1016/j.jhep.2022.
    PubMed    
    
    
    
20. SNIJDERS RJALM, Gevers TJG, Drenth JPH
    The value of surrogate endpoints and predictive markers in autoimmune hepatitis.
    J Hepatol. 2022 Dec 16:S0168-8278(22)03413-4. doi: 10.1016/j.jhep.2022.
    PubMed    
    
    
    
21. EUROPEAN ASSOCIATION FOR THE S
    Corrigendum to 'EASL recommendations on treatment of hepatitis C: Final update of the series(') [J Hepatol 73 (2020) 1170-1218].
    J Hepatol. 2022 Dec 1:S0168-8278(22)03142-7. doi: 10.1016/j.jhep.2022.
    PubMed    
    
    
    
22. YIP TC, Wong VW, Lai MS, Lai JC, et al
    Risk of hepatic decompensation but not hepatocellular carcinoma decreases over time in patients with hepatitis B surface antigen loss.
    J Hepatol. 2022 Dec 1:S0168-8278(22)03314-1. doi: 10.1016/j.jhep.2022.
    PubMed     Abstract available
    
    
    November 2022
23. VAN DER PLUIJM RW, Smits LP, Rebers SP, Schinkel J, et al
    Unmasking of a hepatitis c genotype 3a/1b dual infection in an individual treated with elbasvir/ grazoprevir.
    J Hepatol. 2022 Nov 23:S0168-8278(22)03310-4. doi: 10.1016/j.jhep.2022.
    PubMed    
    
    
    
24. CHOI J
    Reply to: Correspondence on "Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection".
    J Hepatol. 2022;77:1472-1474.
    PubMed    
    
    
    
25. YUEN MF, Locarnini S, Lim TH, Strasser SI, et al
    Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB.
    J Hepatol. 2022;77:1287-1298.
    PubMed     Abstract available
    
    
    October 2022
26. ENGEL B, Jaeckel E, Taubert R
    2022 International Autoimmune Hepatitis Group non-response criteria in autoimmune hepatitis: Quick vs. slow responders.
    J Hepatol. 2022 Oct 12. pii: S0168-8278(22)03138.
    PubMed    
    
    
    
27. TSAI PC, Kuo HT, Hung CH, Tseng KC, et al
    Metformin reduces hepatocellular carcinoma incidence after successful antiviral therapy in patients with diabetes and chronic hepatitis C in Taiwan.
    J Hepatol. 2022 Oct 5. pii: S0168-8278(22)03129.
    PubMed     Abstract available
    
    
    
28. AGARWAL K, Lok J, Gane E
    Antisense oligonucleotides (ASOs) in chronic hepatitis B infection: Opportunities and challenging the orthodoxy.
    J Hepatol. 2022;77:906-908.
    PubMed    
    
    
    
29. LEE SK, Kwon JH, Yoon N, Lee SH, et al
    Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination.
    J Hepatol. 2022;77:1209-1211.
    PubMed    
    
    
    September 2022
30. CARSON JM, Barbieri S, Matthews GV, Dore GJ, et al
    National trends in retreatment of HCV due to reinfection or treatment failure in Australia.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03118.
    PubMed     Abstract available
    
    
    
31. GILLICH N, Zhang Z, Binder M, Urban S, et al
    Effect of variants in LGP2 on MDA5-mediated activation of interferon response and suppression of hepatitis D virus replication.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03113.
    PubMed     Abstract available
    
    
    
32. OLTMANNS C, Liu Z, Mischke J, Tauwaldt J, et al
    Reverse Inflammaging: Long-term effects of HCV cure on biological age.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03115.
    PubMed     Abstract available
    
    
    
33. SUN L, Feng H, Misumi I, Shirasaki T, et al
    Viral protease cleavage of MAVS in genetically modified mice with hepatitis A virus infection.
    J Hepatol. 2022 Sep 21. pii: S0168-8278(22)03120.
    PubMed     Abstract available
    
    
    
34. MARTIN-NAVARRO L, de Andrea C, Sangro B, Argemi J, et al
    In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID19 vaccine-related hepatitis.
    J Hepatol. 2022 Sep 15. pii: S0168-8278(22)03076.
    PubMed    
    
    
    
35. PEETERS M, Schenk J, De Somer T, Roskams T, et al
    Viral clade is associated with severity of symptomatic genotype 3 Hepatitis E virus infections in Belgium, 2010-2018.
    J Hepatol. 2022 Sep 5. pii: S0168-8278(22)03064.
    PubMed     Abstract available
    
    
    
36. YI H, Lin Y, Lu B, Mao Y, et al
    The origin of severe hepatitis of unknown aetiology in children: SARS-CoV-2 or adenovirus?
    J Hepatol. 2022 Sep 3. pii: S0168-8278(22)03063.
    PubMed    
    
    
    
37. SEMMLER G, Lens S, Meyer EL, Baiges A, et al
    Non-invasive tests for clinically significant portal hypertension after HCV cure.
    J Hepatol. 2022 Sep 2. pii: S0168-8278(22)03056.
    PubMed     Abstract available
    
    
    
38. CHO Y, Bukong TN, Tornai D, Babuta M, et al
    Neutrophil extracellular traps contribute to liver damage and increase defective low-density neutrophils in alcoholic hepatitis.
    J Hepatol. 2022 Sep 2. pii: S0168-8278(22)03060.
    PubMed     Abstract available
    
    
    
39. YANG H, Bae SH, Jang JW
    Reply to: 'A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations'.
    J Hepatol. 2022 Sep 1. pii: S0168-8278(22)03057.
    PubMed    
    
    
    August 2022
40. WANG Q, Zhao H, Deng Y, Zheng H, et al
    Validation of Baveno VII criteria for recompensation in entecavir-treated individuals with hepatitis B-related decompensated cirrhosis.
    J Hepatol. 2022 Aug 26. pii: S0168-8278(22)03019.
    PubMed     Abstract available
    
    
    
41. DIETZ J, Mullhaupt B, Buggisch P, Graf C, et al
    Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
    J Hepatol. 2022 Aug 25. pii: S0168-8278(22)03016.
    PubMed     Abstract available
    
    
    
42. JI D, Chen Y, Bi J, Shang Q, et al
    Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)02982.
    PubMed     Abstract available
    
    
    
43. SNIJDERS RJALM, Gevers TJG, Heneghan MA, Drenth JPH, et al
    Defining endpoints that guide treatment in autoimmune hepatitis.
    J Hepatol. 2022 Aug 16. pii: S0168-8278(22)02991.
    PubMed    
    
    
    
44. BRUGGEMANN Y, Klohn M, Todt D
    The pivotal role of CD8+ T cells in hepatitis E virus infection.
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)02986.
    PubMed    
    
    
    
45. AGGARWAL A, Montanari NR, Ramirez R, Diehl L, et al
    Reply to: Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
    J Hepatol. 2022 Aug 14. pii: S0168-8278(22)03000.
    PubMed    
    
    
    
46. DEGASPERI E, Anolli MP, Uceda Renteria SC, Sambarino D, et al
    Bulevirtide monotherapy for 48 Weeks in hdv patients with compensated cirrhosis and clinically significant portal hypertension.
    J Hepatol. 2022 Aug 13. pii: S0168-8278(22)02980.
    PubMed     Abstract available
    
    
    
47. JORGENSEN MH, Cananzi M, Buescher G, Samyn M, et al
    Children with autoimmune liver disease have limited access to age-appropriate drug formulations, results from a European survey.
    J Hepatol. 2022;77:551-553.
    PubMed    
    
    
    
48. WONG AM, Ding X, Wong AM, Xu M, et al
    Unique molecular characteristics of NAFLD-associated liver cancer accentuate beta-catenin/TNFRSF19-mediated immune evasion.
    J Hepatol. 2022;77:410-423.
    PubMed     Abstract available
    
    
    July 2022
49. LI Y, Xiao X, Miao Q, Ma X, et al
    Rapid response predicts complete biochemical response and histological remission in autoimmune hepatitis.
    J Hepatol. 2022 Jul 20. pii: S0168-8278(22)02945.
    PubMed    
    
    
    
50. SEMMLER G, Meyer EL, Mandorfer M
    De-novo-HCC risk stratification after HCV-cure: All roads lead to Rome?
    J Hepatol. 2022 Jul 19. pii: S0168-8278(22)02944.
    PubMed    
    
    
    
51. LIU SY, Yuan C, Tong XM
    Antiviral therapy, HBsAg seroclearance and late recurrence of Hepatitis B-related hepatocellular carcinoma.
    J Hepatol. 2022 Jul 18. pii: S0168-8278(22)02938.
    PubMed    
    
    
    
52. DANDRI M, Volmari A, Lutgehetmann M
    The hepatitis delta virus and chronic hepatitis D.
    J Hepatol. 2022 Jul 15. pii: S0168-8278(22)00337.
    PubMed    
    
    
    
53. PAPATHEODORIDIS GV, Lekakis V, Voulgaris T, Lampertico P, et al
    Hepatitis B Virus Reactivation Associated with New Classes of Immunosuppressants and Immunomodulators: A Systematic Review, Meta-analysis, and Expert Opinion.
    J Hepatol. 2022 Jul 15. pii: S0168-8278(22)02935.
    PubMed     Abstract available
    
    
    
54. BUTI M, Craxi A, Foster GR, Maticic M, et al
    Viral hepatitis Elimination: Towards a hepatitis free world.
    J Hepatol. 2022 Jul 13. pii: S0168-8278(22)02934.
    PubMed    
    
    
    
55. VAN LEEUWEN LPM, de Jong W, Doornekamp L, van Gorp ECM, et al
    Exotic viral hepatitis; a review on epidemiology, pathogenesis, and treatment.
    J Hepatol. 2022 Jul 8. pii: S0168-8278(22)02930.
    PubMed     Abstract available
    
    
    
56. DI DATO F, Di Giorgio A, Mandato C, Maggiore G, et al
    Italian children seem to be spared from the mysterious severe acute hepatitis outbreak: a report by SIGENP Acute Hepatitis Group.
    J Hepatol. 2022 Jul 6. pii: S0168-8278(22)02924.
    PubMed    
    
    
    
57. KARIMI-SARI H, Rezaee-Zavareh MS, Falade-Nwulia O, Lim JK, et al
    Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
    J Hepatol. 2022 Jul 4. pii: S0168-8278(22)02922.
    PubMed    
    
    
    
58. AGARWAL K, Lok J, Carey I, Shivkar Y, et al
    A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'.
    J Hepatol. 2022;77:245-248.
    PubMed     Abstract available
    
    
    
59. LAI MW, Chang YL, Cheng PJ, Chueh HY, et al
    Absence of chronicity in infants born to immunized mothers with occult HBV infection in Taiwan.
    J Hepatol. 2022;77:63-70.
    PubMed     Abstract available
    
    
    
60. HUANG D, Wu D, Wang P, Wang Y, et al
    End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB.
    J Hepatol. 2022;77:42-54.
    PubMed     Abstract available
    
    
    June 2022
61. LAMPERTICO P, Roulot D, Wedemeyer H
    BULEVIRTIDE WITH OR WITHOUT PEGIFNalpha FOR PATIENTS WITH COMPENSATED CHRONIC HEPATITIS DELTA: FROM CLINICAL TRIALS TO REAL LIFE STUDIES.
    J Hepatol. 2022 Jun 22. pii: S0168-8278(22)00373.
    PubMed     Abstract available
    
    
    
62. HOOGEVEEN RC, Dijkstra S, Bartsch LM, Drescher H, et al
    Hepatitis B virus-specific CD4 T-cell responses differentiate functional cure from chronic surface antigen(+) infection.
    J Hepatol. 2022 Jun 15. pii: S0168-8278(22)00366.
    PubMed     Abstract available
    
    
    
63. MEDAS R, Liberal R, Cardoso H, Macedo G, et al
    2022 International Autoimmune Hepatitis Group non-response criteria in autoimmune hepatitis: a too early endpoint?
    J Hepatol. 2022 Jun 15. pii: S0168-8278(22)00367.
    PubMed    
    
    
    
64. YUEN MF, Heo J, Kumada H, Suzuki F, et al
    Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00351.
    PubMed     Abstract available
    
    
    
65. LURZ E, Lenz D, Bufler P, Fichtner A, et al
    Letter to the editor - A peditatric hepatologists' perspective.
    J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00363.
    PubMed    
    
    
    
66. SULKOWSKI MS, Agarwal K, Ma X, Nguyen TT, et al
    Safety and efficacy of vebicorvir administered with entecavir in treatment-naive patients with chronic hepatitis B virus infection.
    J Hepatol. 2022 Jun 10. pii: S0168-8278(22)00348.
    PubMed     Abstract available
    
    
    
67. TANG Y, Chen Y, Chen HN
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance: considerations.
    J Hepatol. 2022 Jun 8. pii: S0168-8278(22)00354.
    PubMed    
    
    
    
68. SZABO G, Thursz M, Shah VH
    Therapeutic advances in alcohol-associated hepatitis.
    J Hepatol. 2022;76:1279-1290.
    PubMed     Abstract available
    
    
    
69. WONG GLH, Gane E, Lok ASF
    How to achieve functional cure of HBV: Stopping NUCs, adding interferon or new drug development?
    J Hepatol. 2022;76:1249-1262.
    PubMed     Abstract available
    
    
    May 2022
70. ZHANG Z, Ni Y, Lempp FA, Walter L, et al
    Hepatitis D virus-induced interferon response and administered interferons control cell division-mediated virus spread.
    J Hepatol. 2022 May 27. pii: S0168-8278(22)00338.
    PubMed     Abstract available
    
    
    
71. KEMMING J, Gundlach S, Panning M, Huzly D, et al
    Mechanisms of CD8+ T cell failure in chronic hepatitis E virus infection.
    J Hepatol. 2022 May 27. pii: S0168-8278(22)00334.
    PubMed     Abstract available
    
    
    
72. ZENG G, Huang J
    The recent outbreak of acute severe hepatitis in children of unknown origin.
    J Hepatol. 2022 May 26. pii: S0168-8278(22)00332.
    PubMed    
    
    
    
73. YOO S, Kim JY, Lim YS, Han S, et al
    Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00329.
    PubMed     Abstract available
    
    
    
74. QIAN Z, Hao X, Xia Y, Yu W, et al
    Rat Hepatitis E virus is a potential zoonotic pathogen to humans.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00327.
    PubMed    
    
    
    
75. KUSHNER T, Djerboua M, Biondi MJ, Feld JJ, et al
    Influence of hepatitis C viral parameters on pregnancy complications and risk of mother-to-child transmission.
    J Hepatol. 2022 May 25. pii: S0168-8278(22)00331.
    PubMed     Abstract available
    
    
    
76. CHU CM, Liaw YF
    Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection.
    J Hepatol. 2022 May 20. pii: S0168-8278(22)00324.
    PubMed    
    
    
    
77. MA Z, de Man RA, Kamar N, Pan Q, et al
    Chronic hepatitis E: advancing research and patient care.
    J Hepatol. 2022 May 20. pii: S0168-8278(22)00319.
    PubMed     Abstract available
    
    
    
78. SEUNG KJ, Franke MF, Hewison C, Huerga H, et al
    Corrigendum to 'High prevalence of hepatitis C infection among multidrug-resistant tuberculosis patients' [J Hepatol 72 (2020) 1028-1029].
    J Hepatol. 2022 May 14. pii: S0168-8278(22)00247.
    PubMed    
    
    
    
79. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
    Corrigendum to 'Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs' [J Hepatol 76 (2022) 549-557].
    J Hepatol. 2022 May 9. pii: S0168-8278(22)00248.
    PubMed    
    
    
    
80. MUCKE MM, Zeuzem S
    The recent outbreak of acute severe hepatitis in children of unknown origin - what is known so far.
    J Hepatol. 2022 May 6. pii: S0168-8278(22)00271.
    PubMed     Abstract available
    
    
    
81. SEMMLER G, Mandorfer M
    Substantiating evidence for HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00267.
    PubMed    
    
    
    
82. BHAGAT N, Verma N, Singh V
    HCC prediction post SVR in HCV patients: many tools yet limited generalizability!
    J Hepatol. 2022 May 5. pii: S0168-8278(22)00264.
    PubMed    
    
    
    
83. LEMON SM
    Hepatitis A: Current view of an ancient disease.
    J Hepatol. 2022 May 2. pii: S0168-8278(21)02091.
    PubMed    
    
    
    
84. SONNEVELD MJ, Chiu SM, Park JY, Brakenhoff SM, et al
    Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels.
    J Hepatol. 2022;76:1042-1050.
    PubMed     Abstract available
    
    
    April 2022
85. BAYLIS SA, O'Flaherty N, Burke L, Hogema B, et al
    Identification of rabbit hepatitis E virus (HEV) and novel HEV clade in Irish blood donors.
    J Hepatol. 2022 Apr 26. pii: S0168-8278(22)00250.
    PubMed    
    
    
    
86. TIAN F, Feld JJ, Feng Z, Sander B, et al
    Feasibility of hepatitis B elimination in high-income countries with ongoing immigration.
    J Hepatol. 2022 Apr 25. pii: S0168-8278(22)00249.
    PubMed     Abstract available
    
    
    
87. BOETTLER T, Csernalabics B, Salie H, Luxenburger H, et al
    SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis.
    J Hepatol. 2022 Apr 21. pii: S0168-8278(22)00234.
    PubMed     Abstract available
    
    
    
88. YUEN MF, Agarwal K, Ma X, Nguyen TT, et al
    Efficacy and safety of vebicorvir administered in virologically-suppressed patients with chronic hepatitis B virus infection.
    J Hepatol. 2022 Apr 20. pii: S0168-8278(22)00238.
    PubMed     Abstract available
    
    
    
89. MAUNG NC, Liew ZHS, Leow WQ, Yeong PSJ, et al
    Severe de novo liver injury after Moderna vaccination - not always autoimmune hepatitis.
    J Hepatol. 2022 Apr 16. pii: S0168-8278(22)00236.
    PubMed    
    
    
    
90. YANG H, Bae SH, Nam H, Lee HL, et al
    A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    J Hepatol. 2022 Apr 7. pii: S0168-8278(22)00208.
    PubMed     Abstract available
    
    
    
91. FRASER DA, Wang X, Lund J, Nikolic N, et al
    A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH.
    J Hepatol. 2022;76:800-811.
    PubMed     Abstract available
    
    
    March 2022
92. NAKATSUKA T, Tateishi R, Nakagomi R, Minami T, et al
    Risk stratification of hepatocellular carcinoma after hepatitis C virus eradication in patients with compensated advanced chronic liver disease in Japan.
    J Hepatol. 2022 Mar 11. pii: S0168-8278(22)00138.
    PubMed    
    
    
    
93. TORGERSEN J, Taddei TH, Lo Re V 3rd
    Reply to: "Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?"
    J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00132.
    PubMed    
    
    
    
94. RUTHER DF, Weltzsch JP, Schramm C, Sebode M, et al
    Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care.
    J Hepatol. 2022 Mar 10. pii: S0168-8278(22)00120.
    PubMed    
    
    
    
95. GEHRING AJ, Mendez P, Richter K, Ertl H, et al
    Immunological Biomarker Discovery in Cure Regimens for Chronic Hepatitis B Virus Infection.
    J Hepatol. 2022 Mar 5. pii: S0168-8278(22)00127.
    PubMed     Abstract available
    
    
    February 2022
96. MONTANARI NR, Ramirez R, Aggarwal A, van Buuren N, et al
    Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection.
    J Hepatol. 2022 Feb 23. pii: S0168-8278(22)00123.
    PubMed     Abstract available
    
    
    
97. RIVERO-JUAREZ A, Frias M, Perez AB, Pineda JA, et al
    Orthohepevirus C infection as an emerging cause of acute hepatitis in Spain: first report in Europe.
    J Hepatol. 2022 Feb 12. pii: S0168-8278(22)00075.
    PubMed     Abstract available
    
    
    
98. MUELLER PP, Chen Q, Ayer T, Nemutlu G, et al
    Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00074.
    PubMed     Abstract available
    
    
    
99. LESLIE J, Geh D, Elsharkawy AM, Mann DA, et al
    Metabolic dysfunction and cancer in HCV: shared pathways and mutual interactions.
    J Hepatol. 2022 Feb 11. pii: S0168-8278(22)00076.
    PubMed     Abstract available
    
    
    
100. MONTANO-LOZA AJ, Ronca V, Ebadi M, Hansen BE, et al
     Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation.
     J Hepatol. 2022 Feb 7. pii: S0168-8278(22)00067.
     PubMed     Abstract available
     
     
     
101. JACHS M, Scheiner B, Pinter M
     Letter to the editor: Immunotherapy for hepatocellular carcinoma in a patient with hepatitis B virus and hepatitis delta virus coinfection.
     J Hepatol. 2022 Feb 3. pii: S0168-8278(22)00030.
     PubMed    
     
     
     January 2022
102. BEHRENDT P, Friesland M, Wissmann JE, Kinast V, et al
     Hepatitis E virus is highly resistant to alcohol-based disinfectants.
     J Hepatol. 2022 Jan 24. pii: S0168-8278(22)00019.
     PubMed     Abstract available
     
     
     
103. GALLARD C, Lebsir N, Khursheed H, Reungoat E, et al
     Heparanase is upregulated by HCV and favors its replication.
     J Hepatol. 2022 Jan 24. pii: S0168-8278(22)00021.
     PubMed     Abstract available
     
     
     
104. WONG YJ, Nguyen MH
     Is it safe to treat chronic hepatitis C patients with decompensated cirrhosis with PI-based DAA?
     J Hepatol. 2022 Jan 21. pii: S0168-8278(22)00008.
     PubMed    
     
     
     
105. PAPE S, Snijders RJ, Gevers TJ, Chazouilleres O, et al
     Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group.
     J Hepatol. 2022 Jan 20. pii: S0168-8278(22)00012.
     PubMed     Abstract available
     
     
     
106. SHEKHTMAN L, Cotler SJ, Ploss A, Dahari H, et al
     Mathematical modeling suggests that entry-inhibitor Bulevirtide may interfere with hepatitis D virus clearance from circulation.
     J Hepatol. 2022 Jan 4. pii: S0168-8278(21)02307.
     PubMed    
     
     
     
107. PIHL AF, Feng S, Offersgaard A, Alzua GP, et al
     Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice.
     J Hepatol. 2022 Jan 3. pii: S0168-8278(21)02303.
     PubMed     Abstract available
     
     
     December 2021
108. BEAUMONT E, Larochette V, Preisser L, Miot C, et al
     IL-26 inhibits hepatitis C virus replication in hepatocytes.
     J Hepatol. 2021 Dec 21. pii: S0168-8278(21)02253.
     PubMed     Abstract available
     
     
     
109. SEMMLER G, Meyer EL, Kozbial K, Schwabl P, et al
     HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease.
     J Hepatol. 2021 Dec 3. pii: S0168-8278(21)02234.
     PubMed     Abstract available
     
     
     
110. ZHANG M, Zhang Z, Imamura M, Osawa M, et al
     Infection courses, virological features and IFN-alpha responses of HBV genotypes in cell culture and animal models.
     J Hepatol. 2021;75:1335-1345.
     PubMed     Abstract available
     
     
     November 2021
111. SANDUZZI-ZAMPARELLI M, Marino Z, Lens S, Sapena V, et al
     Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules.
     J Hepatol. 2021 Nov 29. pii: S0168-8278(21)02228.
     PubMed     Abstract available
     
     
     
112. DE MARTIN E, Duclos-Vallee JC
     Reply to "validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis".
     J Hepatol. 2021 Nov 10. pii: S0168-8278(21)02167.
     PubMed    
     
     
     
113. TENG Y, Xu Z, Zhao K, Zhong Y, et al
     Novel function of SART1 in HNF4alpha transcriptional regulation contributes to its antiviral role during HBV infection.
     J Hepatol. 2021;75:1072-1082.
     PubMed     Abstract available
     
     
     October 2021
114. LOGLIO A, Ferenci P, Uceda Renteria SC, Tham CYL, et al
     Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis.
     J Hepatol. 2021 Oct 23. pii: S0168-8278(21)02119.
     PubMed     Abstract available
     
     
     
115. YUAN S, Yang Y, Hu R
     The Unfolding Multiomics Landscapes of HBV (Hepatitis B Virus)-Host Interactions.
     J Hepatol. 2021 Oct 11. pii: S0168-8278(21)02101.
     PubMed    
     
     
     
116. YEUNG A, Palmateer NE, Dillon JF, McDonald SA, et al
     Population-level estimates of hepatitis C reinfection post scale-up of direct-acting antivirals among people who inject drugs.
     J Hepatol. 2021 Oct 8. pii: S0168-8278(21)02103.
     PubMed     Abstract available
     
     
     
117. TUN GS, Gleeson D, Dube A, Al-Joudeh A, et al
     Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed.
     J Hepatol. 2021 Oct 4. pii: S0168-8278(21)02093.
     PubMed    
     
     
     
118. KIM HY, Lampertico P, Nam JY, Lee HC, et al
     An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B.
     J Hepatol. 2021 Oct 1. pii: S0168-8278(21)02087.
     PubMed     Abstract available
     
     
     
119. MALLET V, Beeker N, Bouam S, Sogni P, et al
     Prognosis of French COVID-19 patients with chronic liver disease: A national retrospective cohort study for 2020.
     J Hepatol. 2021;75:848-855.
     PubMed     Abstract available
     
     
     
120. WANG GP, Schnell GL, Kort JJ, Sidhu GS, et al
     Linkage of resistance-associated substitutions in GT1 sofosbuvir + NS5A inhibitor failures treated with glecaprevir/pibrentasvir.
     J Hepatol. 2021;75:820-828.
     PubMed     Abstract available
     
     
     
121. MEIER MA, Calabrese D, Suslov A, Terracciano LM, et al
     Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load.
     J Hepatol. 2021;75:840-847.
     PubMed     Abstract available
     
     
     September 2021
122. CACOUB P, Comarmond C, Vieira M, Regnier P, et al
     HCV-related lymphoproliferative disorders in the direct-acting antivirals era: from mixed cryoglobulinemia to B-cell lymphoma.
     J Hepatol. 2021 Sep 29. pii: S0168-8278(21)02084.
     PubMed     Abstract available
     
     
     
123. RAHIM MN, Heneghan MA
     Reply to "The Search for Optimum Thiopurine Metabolite Levels in Autoimmune Hepatitis Continues".
     J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02046.
     PubMed    
     
     
     
124. D'AMBROSIO R, Degasperi E, Anolli MP, Fanetti I, et al
     Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
     J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02043.
     PubMed     Abstract available
     
     
     
125. CHOI WM, Yip TC, Lim YS, Wong GL, et al
     Methodological Challenges in Meta-Analysis to Assess the Risk of Hepatocellular Carcinoma Across Chronic Hepatitis B Treatments.
     J Hepatol. 2021 Sep 27. pii: S0168-8278(21)02079.
     PubMed     Abstract available
     
     
     
126. KIM HS, Yu X, Kramer J, Thrift AP, et al
     Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States.
     J Hepatol. 2021 Sep 23. pii: S0168-8278(21)02039.
     PubMed     Abstract available
     
     
     
127. MALLET V, Scarano Pereira JP, Martinino A, Roque-Afonso AM, et al
     The rise of the hepatitis E virus.
     J Hepatol. 2021 Sep 16. pii: S0168-8278(21)00303.
     PubMed    
     
     
     
128. LACKNER C, Stauber RE, Tiniakos D
     Reply to: Prognostic value of histologic parameters in alcoholic hepatitis: a word of caution.
     J Hepatol. 2021 Sep 16. pii: S0168-8278(21)02035.
     PubMed    
     
     
     
129. GAO Y, You M, Fu J, Tian M, et al
     Intratumoral stem-like CCR4+ regulatory T cells orchestrate the immunosuppressive microenvironment in HCC associated with hepatitis B.
     J Hepatol. 2021 Sep 12. pii: S0168-8278(21)02027.
     PubMed     Abstract available
     
     
     August 2021
130. YE Q, Kam LY, Yeo YH, Dang N, et al
     Substantial gaps in evaluation and treatment of patients with hepatitis B in the US.
     J Hepatol. 2021 Aug 30. pii: S0168-8278(21)02014.
     PubMed     Abstract available
     
     
     
131. CORDES AK, Goudeva L, Lutgehetmann M, Wenzel JJ, et al
     Risk of transfusion-transmitted hepatitis E virus infection from pool-tested platelets and plasma.
     J Hepatol. 2021 Aug 27. pii: S0168-8278(21)02013.
     PubMed     Abstract available
     
     
     
132. LIN S, Hall A, Kumar R, Quaglia A, et al
     Validation of the SURFASA score to define steroid responsiveness in patients with acute autoimmune hepatitis.
     J Hepatol. 2021 Aug 25. pii: S0168-8278(21)02008.
     PubMed    
     
     
     
133. ZHOU T, Fronhoffs F, Dold L, Strassburg CP, et al
     New-Onset Autoimmune Hepatitis following mRNA Covid-19 Vaccination in a 36-year-old woman with Primary Sclerosing Cholangitis - should we be more vigilant?
     J Hepatol. 2021 Aug 24. pii: S0168-8278(21)02000.
     PubMed    
     
     
     
134. DO CARMO RF, de Souza CDF
     Impact of the COVID-19 pandemic on hepatitis C diagnosis in Brazil: Is the global hepatitis C elimination strategy at risk?
     J Hepatol. 2021 Aug 23. pii: S0168-8278(21)01999.
     PubMed    
     
     
     
135. FERNANDO B
     Autoimmune Hepatitis Developing After Coronavirus Disease 2019 (COVID-19) Vaccine: One or Even Several Swallows Do Not Make a Summer.
     J Hepatol. 2021 Aug 9. pii: S0168-8278(21)01965.
     PubMed    
     
     
     
136. XU H, Locarnini S, Wong D, Hammond R, et al
     Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A.
     J Hepatol. 2021 Aug 6. pii: S0168-8278(21)01959.
     PubMed     Abstract available
     
     
     July 2021
137. MISUMI I, Mitchell JE, Lund MM, Cullen JM, et al
     T cells protect against hepatitis A virus infection and limit infection-induced liver injury.
     J Hepatol. 2021 Jul 28. pii: S0168-8278(21)01949.
     PubMed     Abstract available
     
     
     
138. DELTENRE P, Marot A
     Prognostic value of histologic parameters in alcoholic hepatitis: a word of caution.
     J Hepatol. 2021 Jul 20. pii: S0168-8278(21)01912.
     PubMed    
     
     
     
139. BORGIA SM, Shafran SD
     Reply to: "Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy".
     J Hepatol. 2021 Jul 19. pii: S0168-8278(21)01908.
     PubMed    
     
     
     
140. KIRCHNER T, Jaeckel E, Falk CS, Eiz-Vesper B, et al
     SARS-CoV-2-specific immunity in immunosuppressed COVID-19 convalescents with autoimmune hepatitis.
     J Hepatol. 2021 Jul 17. pii: S0168-8278(21)01911.
     PubMed    
     
     
     
141. MONTALDO C, Terri M, Riccioni V, Battistelli C, et al
     Fibrogenic signals persist in DAA-treated HCV patients after sustained virological response.
     J Hepatol. 2021 Jul 13. pii: S0168-8278(21)01901.
     PubMed     Abstract available
     
     
     
142. LODATO F, Larocca A, D'Errico A, Cennamo V, et al
     AN ANUSUAL CASE OF ACUTE CHOLESTATIC HEPATITIS AFTER m-RNABNT162b2 (COMIRNATY) SARS-CoV-2 VACCINE: COINCIDENCE, AUTOIMMUNITY OR DRUG RELATED LIVER INJURY?
     J Hepatol. 2021 Jul 10. pii: S0168-8278(21)01904.
     PubMed    
     
     
     
143. MCSHANE C, Kiat C, Rigby J, Crosbie O, et al
     The mRNA COVID-19 vaccine - a rare trigger of Autoimmune Hepatitis?
     J Hepatol. 2021 Jul 7. pii: S0168-8278(21)01896.
     PubMed    
     
     
     
144. LLEWELLYN HP, Arat S, Gao J, Wen J, et al
     T cells and monocyte-derived myeloid cells mediate immunotherapy-related hepatitis in a mouse model.
     J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01887.
     PubMed     Abstract available
     
     
     
145. BOLIA R, Srivastava A
     The Search For Optimum Thiopurine Metabolite Levels in Autoimmune Hepatitis Continues....
     J Hepatol. 2021 Jul 6. pii: S0168-8278(21)01890.
     PubMed    
     
     
     
146. GRANITO A, Muratori P, Muratori L
     Acute-on-chronic liver failure: a complex clinical entity in patients with autoimmune hepatitis.
     J Hepatol. 2021 Jul 3. pii: S0168-8278(21)01884.
     PubMed    
     
     
     
147. YUAN S, Liao G, Zhang M, Zhu Y, et al
     Translatomic profiling reveals novel self-restricting virus-host interactions during HBV infection.
     J Hepatol. 2021;75:74-85.
     PubMed     Abstract available
     
     
     June 2021
148. PAPATHEODORIDI M, Papatheodoridis G
     New concepts in the finite oral antiviral therapy in HBeAg-negative chronic hepatitis B.
     J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00440.
     PubMed    
     
     
     
149. CLAYTON-CHUBB D, Schneider D, Freeman E, Kemp W, et al
     Comment to the letter of Bril F et al. "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?"
     J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00427.
     PubMed    
     
     
     
150. QUITT O, Luo S, Meyer M, Xie Z, et al
     T-cell engager antibodies enable T cells to control HBV infection and to target HBsAg-positive hepatoma in mice.
     J Hepatol. 2021 Jun 22. pii: S0168-8278(21)00443.
     PubMed     Abstract available
     
     
     
151. ARAB JP, Diaz LA, Baeza N, Idalsoaga F, et al
     IDENTIFICATION OF OPTIMAL THERAPEUTIC WINDOW FOR STEROID USE IN SEVERE ALCOHOL-ASSOCIATED HEPATITIS: A WORLDWIDE STUDY.
     J Hepatol. 2021 Jun 21. pii: S0168-8278(21)00439.
     PubMed     Abstract available
     
     
     
152. TAN CK, Wong YJ, Wang LM, Ang TL, et al
     Autoimmune hepatitis following COVID-19 Vaccination: true causality or mere association?
     J Hepatol. 2021 Jun 18. pii: S0168-8278(21)00424.
     PubMed    
     
     
     
153. BRIL F, Fettig DM
     Response to letter to the editor by Capecchi et al. "Comment to the letter of Bril F et al. "Autoimmune Hepatitis Developing After Coronavirus Disease 2019 (COVID-19) Vaccine: Causality or Casualty?"
     J Hepatol. 2021 Jun 16. pii: S0168-8278(21)00423.
     PubMed    
     
     
     
154. BOU SALEH M, Louvet A, Ntandja-Wandji LC, Boleslawski E, et al
     Loss of hepatocyte identity following aberrant YAP activation: a key mechanism in alcoholic hepatitis.
     J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00416.
     PubMed     Abstract available
     
     
     
155. LONDONO MC, Gratacos-Gines J, Saez-Penataro J
     Another case of autoimmune hepatitis after SARS-CoV-2 vaccination. Still casualty?
     J Hepatol. 2021 Jun 12. pii: S0168-8278(21)00417.
     PubMed    
     
     
     
156. MARCOS-FOSCH C, Cabezas J, Crespo J, Buti M, et al
     Anti-epileptic drugs and hepatitis C therapy: real world experience.
     J Hepatol. 2021 Jun 11. pii: S0168-8278(21)00414.
     PubMed    
     
     
     
157. ROCCO A, Sgamato C, Compare D, Nardone G, et al
     Autoimmune hepatitis following sars-cov-2 VACCINE: MAY not be a casualty.
     J Hepatol. 2021 Jun 8. pii: S0168-8278(21)00412.
     PubMed    
     
     
     
158. JANJUA NZ, Wong S, Abdia Y, Jeong D, et al
     Impact of direct-acting antivirals for HCV on mortality in a large population-based cohort study.
     J Hepatol. 2021 Jun 4. pii: S0168-8278(21)00401.
     PubMed     Abstract available
     
     
     
159. LI J, Liang X, You S, Feng T, et al
     Development and validation of a new prognostic score for hepatitis B virus-related acute-on-chronic liver failure.
     J Hepatol. 2021 Jun 3. pii: S0168-8278(21)00399.
     PubMed     Abstract available
     
     
     
160. DING ZY, Li GX, Chen L, Shu C, et al
     Association of liver abnormalities with in-hospital mortality in patients with COVID-19.
     J Hepatol. 2021;74:1295-1302.
     PubMed     Abstract available
     
     
     
161. SARRAZIN C
     Treatment failure with DAA therapy: Importance of resistance.
     J Hepatol. 2021;74:1472-1482.
     PubMed     Abstract available
     
     
     
162. CHEN J, Liu B, Tang X, Zheng X, et al
     Role of core protein mutations in the development of occult HBV infection.
     J Hepatol. 2021;74:1303-1314.
     PubMed     Abstract available
     
     
     May 2021
163. MATHURIN P
     Early liver transplantation for acute alcoholic hepatitis: we can't say no.
     J Hepatol. 2021 May 28. pii: S0168-8278(21)00354.
     PubMed     Abstract available
     
     
     
164. KOLAMUNNAGE-DONA R, Berhane S, Potts H, Williams EH, et al
     Sorafenib is associated with a reduced rate of tumour growth and liver function deterioration in HCV-induced hepatocellular carcinoma.
     J Hepatol. 2021 May 27. pii: S0168-8278(21)00350.
     PubMed     Abstract available
     
     
     
165. HUANG CF, Wei YJ, Wu YT, Chiu YW, et al
     Real world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy.
     J Hepatol. 2021 May 26. pii: S0168-8278(21)00351.
     PubMed    
     
     
     
166. MARTINEZ MG, Boyd A, Combe E, Testoni B, et al
     Covalently closed circular DNA: the ultimate therapeutic target for curing Hepatitis B virus infections.
     J Hepatol. 2021 May 26. pii: S0168-8278(21)00348.
     PubMed     Abstract available
     
     
     
167. DE MARTIN E, Duclos-Vallee JC
     Reply to "Acute severe autoimmune hepatitis - timing for steroids and role of other immunosuppressive agents".
     J Hepatol. 2021 May 26. pii: S0168-8278(21)00345.
     PubMed    
     
     
     
168. MATTHEWS GV, Bhagani S, Van der Valk M, Rockstroh J, et al
     Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.
     J Hepatol. 2021 May 20. pii: S0168-8278(21)00336.
     PubMed     Abstract available
     
     
     
169. RODRIGUES PM, Olaizola P, Banales JM
     Unscrambling a novel pathogenic role for interleukin-20 in acute hepatitis and bacterial infection: A double-edged sword?
     J Hepatol. 2021 May 10. pii: S0168-8278(21)00183.
     PubMed    
     
     
     
170. SHAH R, Ahovegbe L, Niebel M, Shepherd J, et al
     Non-epidemic HCV genotypes in low- and middle-income countries and the risk of resistance to current direct-acting antiviral regimens.
     J Hepatol. 2021 May 8. pii: S0168-8278(21)00310.
     PubMed     Abstract available
     
     
     
171. CRESPO J, Diaz-Gonzalez A, Cabezas J
     HCV detection is possible during SARS CoV-2 testing; and throughout COVID-19 vaccination?
     J Hepatol. 2021 May 7. pii: S0168-8278(21)00308.
     PubMed    
     
     
     
172. CAPECCHI PL, Lazzerini PE, Brillanti S
     Comment to the letter of Bril F et al. "Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?"
     J Hepatol. 2021 May 5. pii: S0168-8278(21)00304.
     PubMed    
     
     
     
173. ZENG DY, Li JM, Lin S, Dong X, et al
     Global burden of acute viral hepatitis and its association with socioeconomic development status, 1990-2019.
     J Hepatol. 2021 May 4. pii: S0168-8278(21)00300.
     PubMed     Abstract available
     
     
     
174. BREMER W, Blasczyk H, Yin X, Duron ES, et al
     Resolution of hepatitis E virus infection in CD8+ T cell depleted rhesus macaques.
     J Hepatol. 2021 May 4. pii: S0168-8278(21)00301.
     PubMed     Abstract available
     
     
     
175. REIG M, Cabibbo G
     Antiviral therapy in the palliative setting of HCC (BCLC-B and -C).
     J Hepatol. 2021;74:1225-1233.
     PubMed     Abstract available
     
     
     
176. HIGASHI-KUWATA N, Hayashi S, Kumamoto H, Ogata-Aoki H, et al
     Identification of a novel long-acting 4'-modified nucleoside reverse transcriptase inhibitor against HBV.
     J Hepatol. 2021;74:1075-1086.
     PubMed     Abstract available
     
     
     
177. PAPATHEODORIDI M, Hiriart JB, Lupsor-Platon M, Bronte F, et al
     Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease.
     J Hepatol. 2021;74:1109-1116.
     PubMed     Abstract available
     
     
     April 2021
178. LIBERAL R, Macedo G
     Acute severe autoimmune hepatitis - timing for steroids and role of other immunosuppressive agents.
     J Hepatol. 2021 Apr 29. pii: S0168-8278(21)00297.
     PubMed    
     
     
     
179. DIETZ J, Sarrazin C
     Reply to "glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings".
     J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00252.
     PubMed    
     
     
     
180. LLAMOSAS-FALCON L, Shield KD, Gelovany M, Hasan OSM, et al
     Impact of alcohol on the progression of HCV-related liver disease: A systematic review and meta-analysis.
     J Hepatol. 2021 Apr 20. pii: S0168-8278(21)00253.
     PubMed     Abstract available
     
     
     
181. SONNEVELD MJ, Veldhuijzen IK, van de Laar T, Op de Coul ELM, et al
     DECREASE IN VIRAL HEPATITIS DIAGNOSES DURING THE COVID-19 PANDEMIC IN THE NETHERLANDS.
     J Hepatol. 2021 Apr 19. pii: S0168-8278(21)00250.
     PubMed    
     
     
     
182. CANDELS LS, Rahim MN, Shah S, Heneghan MA, et al
     Towards personalised medicine in autoimmune hepatitis: Measurement of thiopurine metabolites results in higher biochemical response rates compared to standard weight-based dosing of thiopurine therapy.
     J Hepatol. 2021 Apr 16. pii: S0168-8278(21)00227.
     PubMed     Abstract available
     
     
     
183. BRIL F, Al Diffalha S, Dean M, Fettig DM, et al
     Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?
     J Hepatol. 2021 Apr 13. pii: S0168-8278(21)00237.
     PubMed    
     
     
     
184. WANG W, Lempp FA, Schlund F, Walter L, et al
     Assembly and infection efficacy of hepatitis B virus surface protein exchanges in eight hepatitis D virus genotype isolates.
     J Hepatol. 2021 Apr 9. pii: S0168-8278(21)00229.
     PubMed     Abstract available
     
     
     
185. GERLICH W
     Hepatitis B virus - an anaerobic organism?
     J Hepatol. 2021 Apr 2. pii: S0168-8278(21)00166.
     PubMed    
     
     
     
186. DIETZ J, Di Maio VC, de Salazar A, Merino D, et al
     Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
     J Hepatol. 2021;74:801-810.
     PubMed     Abstract available
     
     
     March 2021
187. LIAO SH, Chen CL, Hsu CY, Chien KL, et al
     Long-term Effectiveness of Population-wide Multifaceted Interventions for Hepatocellular Carcinoma in Taiwan.
     J Hepatol. 2021 Mar 6. pii: S0168-8278(21)00163.
     PubMed     Abstract available
     
     
     
188. CHENG ST, Hu JL, Ren JH, Yu HB, et al
     Dicoumarol, an NQO1 inhibitor, blocks cccDNA transcription by promoting degradation of HBx.
     J Hepatol. 2021;74:522-534.
     PubMed     Abstract available
     
     
     February 2021
189. LIEBE R, Esposito I, Bock HH, Dahl SV, et al
     Diagnosis and management of secondary causes of steatohepatitis.
     J Hepatol. 2021 Feb 9. pii: S0168-8278(21)00096.
     PubMed     Abstract available
     
     
     
190. IOANNOU GN
     HCC surveillance after SVR in patients with F3/F4 fibrosis.
     J Hepatol. 2021;74:458-465.
     PubMed     Abstract available
     
     
     January 2021
191. SRIDHAR S, Situ J, Cai JP, Yip CC, et al
     Multimodal investigation of rat hepatitis E virus antigenicity: implications for infection, diagnostics, and vaccine efficacy.
     J Hepatol. 2021 Jan 15. pii: S0168-8278(21)00013.
     PubMed     Abstract available
     
     
     November 2020
192. TREBICKA J, Fernandez J, Papp M, Caraceni P, et al
     PREDICT identifies precipitating events associated with the clinical course of acutely decompensated cirrhosis.
     J Hepatol. 2020 Nov 20. pii: S0168-8278(20)33772.
     PubMed     Abstract available
     
     
     October 2020
193. WANG H, Wen B, Chang X, Wu Q, et al
     Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis.
     J Hepatol. 2020 Oct 8. pii: S0168-8278(20)33678.
     PubMed     Abstract available
     
     
     March 2020
194. BUTT AA, Yan P, Shaikh OS, Lo Re V 3rd, et al
     Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
     J Hepatol. 2020 Mar 4. pii: S0168-8278(20)30120.
     PubMed     Abstract available
     
     
     February 2020
195. HAN JW, Sung PS, Hong SH, Lee H, et al
     IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses.
     J Hepatol. 2020 Feb 20. pii: S0168-8278(20)30107.
     PubMed     Abstract available
     
     
     
196. YEH ML, Huang CF, Huang CI, Holmes JA, et al
     Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection.
     J Hepatol. 2020 Feb 13. pii: S0168-8278(20)30074.
     PubMed     Abstract available
     
     
     
197. LAMPERTICO P, Carrion JA, Curry M, Turnes J, et al
     Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis.
     J Hepatol. 2020 Feb 12. pii: S0168-8278(20)30072.
     PubMed     Abstract available
     
     
     
198. VIBERT E, Schwartz M, Olthoff KM
     Advances in resection and transplantation for hepatocellular carcinoma.
     J Hepatol. 2020;72:262-276.
     PubMed     Abstract available
     
     
     
199. SINGAL AG, Lampertico P, Nahon P
     Epidemiology and surveillance for hepatocellular carcinoma: New trends.
     J Hepatol. 2020;72:250-261.
     PubMed     Abstract available
     
     
     January 2020
200. TSENG TC, Liu CJ, Chang CT, Su TH, et al
     HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis.
     J Hepatol. 2020 Jan 29. pii: S0168-8278(20)30029.
     PubMed     Abstract available
     
     
     December 2019
201. HOORNENBORG E, Coyer L, Boyd A, Alfons Achterbergh RC, et al
     High incidence of HCV in HIV-negative men who have sex with men using pre-exposure prophylaxis.
     J Hepatol. 2019 Dec 17. pii: S0168-8278(19)30719.
     PubMed     Abstract available
     
     
     
202. AVERHOFF F, Shadaker S, Gamkrelidze A, Kuchuloria T, et al
     Progress and Challenges in a Pioneering Hepatitis C Elimination Program in the Country of Georgia, 2015-2018.
     J Hepatol. 2019 Dec 4. pii: S0168-8278(19)30710.
     PubMed     Abstract available
     
     
     November 2019
203. LIU CH, Lee MH, Lin JW, Liu CJ, et al
     Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct acting antivirals.
     J Hepatol. 2019 Nov 29. pii: S0168-8278(19)30701.
     PubMed     Abstract available
     
     
     
204. BRASHER NA, Eltahla AA, Underwood A, Boo I, et al
     B cell immunodominance in primary hepatitis C virus infection.
     J Hepatol. 2019 Nov 27. pii: S0168-8278(19)30698.
     PubMed     Abstract available
     
     
     
205. HAJARIZADEH B, Cunningham EB, Valerio H, Martinello M, et al
     Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis.
     J Hepatol. 2019 Nov 27. pii: S0168-8278(19)30699.
     PubMed     Abstract available
     
     
     
206. SHIHA G, Soliman R, Mikhail NN, Easterbrook P, et al
     Educate, Test and Treat Model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
     J Hepatol. 2019 Nov 14. pii: S0168-8278(19)30672.
     PubMed     Abstract available
     
     
     
207. HAMMOUTENE A, Biquard L, Lasselin J, Kheloufi M, et al
     A defect in endothelial autophagy occurs in patients with nonalcoholic steatohepatitis and promotes inflammation and fibrosis.
     J Hepatol. 2019 Nov 11. pii: S0168-8278(19)30669.
     PubMed     Abstract available
     
     
     
208. BROWN RS JR, Buti M, Rodrigues L, Chulanov V, et al
     Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: the EXPEDITION-8 trial.
     J Hepatol. 2019 Nov 1. pii: S0168-8278(19)30647.
     PubMed     Abstract available
     
     
     October 2019
209. DORE GJ, Feld JJ, Thompson A, Martinello M, et al
     Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.
     J Hepatol. 2019 Oct 23. pii: S0168-8278(19)30612.
     PubMed     Abstract available
     
     
     
210. PONS M, Rodriguez-Tajes S, Esteban JI, Marino Z, et al
     Non-invasive prediction of liver related events in HCV compensated advanced chronic liver disease patients after oral antivirals.
     J Hepatol. 2019 Oct 17. pii: S0168-8278(19)30606.
     PubMed     Abstract available
     
     
     
211. LI Y, Tang L, Guo L, Chen C, et al
     CXCL13-mediated recruitment of intrahepatic CXCR5+CD8+T cells favors viral control in chronic HBV infection.
     J Hepatol. 2019 Oct 11. pii: S0168-8278(19)30602.
     PubMed     Abstract available
     
     
     September 2019
212. CLEMENTS O, Eliahoo J, Un Kim J, Taylor-Robinson SD, et al
     Risk Factors for Intrahepatic and Extrahepatic Cholangiocarcinoma: a systematic review and meta-analysis.
     J Hepatol. 2019 Sep 16. pii: S0168-8278(19)30543.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: